HIV

STI clinics are an important setting for the provision of HIV pre-exposure prophylaxis (PrEP) and are also one of the fastest growing categories of the 340B drug discount program. The HIV+Hepatitis Policy Institute engaged BRG to determine how STD clinics are using the 340B program to fight HIV and viral hepatitis. BRG examined STD clinic enrollment trends over time using the HRSA 340B database in order to learn what types of clinics were enrolling and how they were able to obtain their 340B designation (direct or indirect funding). BRG also examined Medicaid claims in five states and Medicare claims nationally to identify which drugs were prescribed by providers at enrolled STD clinics, comparing PrEP and HIV/viral hepatitis treatment drugs with other drugs.